Description: SynDevRx leads the field of Metabo-Oncology, exploiting the link between cancer and metabolic dysfunction to improve patient outcomes.
1 Broadway # 14, Cambridge, MA 02142
Cancer uses metabolic hormones (e.g., insulin, leptin) caused by overweight, diabetes, or pre-diabetes to promote cancer progression and metastases . Yet, the co-occurence of cancer and insulin that affects millions of cancer patients worldwide is overlooked as a major contributor to cancer progression . What’s worse, many anti-cancer treatments cause metabolic dysfunction which can limit drug effectiveness and even lead to treatment resistance. SynDevRx – the leader in the emerging field of metabo-oncolo
More on metabo-oncology